VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

MR Mirza; D. Chase; B.M. Slomovitz; R.D. Christensen; Z. Novák; D. Black; L. Gilbert; S. Sharma; G. Valabrega; Lisa M. Landrum; L.C. Hanker; A. Stuckey; I.A. Boere; M. Gold; S.E. Gill; B.J. Monk; Z. He; S. Stevens; R.L. Coleman; M.A. Powell

doi:10.1016/j.annonc.2023.02.008

VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

MR Mirza(Copenhagen University Hospital), D. Chase(Creighton University), B.M. Slomovitz(Florida International University), R.D. Christensen(University of Southern Denmark), Z. Novák(National Institute of Oncology), D. Black(Louisiana State University Health Sciences Center Shreveport), L. Gilbert(McGill University Health Centre), S. Sharma(Adventist Hinsdale Hospital), G. Valabrega(A. O. Ordine Mauriziano di Torino), Lisa M. Landrum(Indiana University Health), L.C. Hanker(University Hospital Schleswig-Holstein), A. Stuckey(Providence College), I.A. Boere(Erasmus MC Cancer Institute), M. Gold(Oklahoma Cancer Specialists and Research Institute), S.E. Gill, B.J. Monk(Creighton University), Z. He(GlaxoSmithKline (United States)), S. Stevens, R.L. Coleman(The US Oncology Network), M.A. Powell(National Cancer Institute)

Annals of Oncology

March 27, 2023

10.1016/j.annonc.2023.02.008

Cited by 3Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis